Acute hypertriglyceridemia in patients with COVID‐19 receiving tocilizumab
2020; Wiley; Volume: 92; Issue: 10 Linguagem: Inglês
10.1002/jmv.25907
ISSN1096-9071
AutoresAustin Morrison, Joseph M. Johnson, Mayur Ramesh, Patrick Bradley, Jeffery Jennings, Zachary Smith,
Tópico(s)Inflammasome and immune disorders
ResumoJournal of Medical VirologyVolume 92, Issue 10 p. 1791-1792 LETTER TO THE EDITOR Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab Austin R. Morrison PharmD, Austin R. Morrison PharmD Department of Pharmacy, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorJoseph M. Johnson PharmD, BCCCP, Joseph M. Johnson PharmD, BCCCP Department of Pharmacy, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorMayur Ramesh MD, Mayur Ramesh MD Department of Infectious Diseases, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorPatrick Bradley MD, Patrick Bradley MD Pulmonary and Critical Care Medicine Division, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorJeffery Jennings MD, Jeffery Jennings MD Pulmonary and Critical Care Medicine Division, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorZachary R. Smith PharmD, BCPS, BCCCP, Corresponding Author Zachary R. Smith PharmD, BCPS, BCCCP [email protected] orcid.org/0000-0001-8221-1108 Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan Correspondence Zachary R. Smith, PharmD, BCPS, BCCCP, Department of Pharmacy, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202. Email: [email protected]Search for more papers by this author Austin R. Morrison PharmD, Austin R. Morrison PharmD Department of Pharmacy, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorJoseph M. Johnson PharmD, BCCCP, Joseph M. Johnson PharmD, BCCCP Department of Pharmacy, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorMayur Ramesh MD, Mayur Ramesh MD Department of Infectious Diseases, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorPatrick Bradley MD, Patrick Bradley MD Pulmonary and Critical Care Medicine Division, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorJeffery Jennings MD, Jeffery Jennings MD Pulmonary and Critical Care Medicine Division, Henry Ford Hospital, Detroit, MichiganSearch for more papers by this authorZachary R. Smith PharmD, BCPS, BCCCP, Corresponding Author Zachary R. Smith PharmD, BCPS, BCCCP [email protected] orcid.org/0000-0001-8221-1108 Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan Correspondence Zachary R. Smith, PharmD, BCPS, BCCCP, Department of Pharmacy, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI 48202. Email: [email protected]Search for more papers by this author First published: 21 April 2020 https://doi.org/10.1002/jmv.25907Citations: 62Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookxLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020. https://doi.org/10.1002/jmv.25801 10.1002/jmv.25801 Web of Science®Google Scholar 2McCreary EK, Pouge JM. COVID-19 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020; 7(4):ofaa105. 10.1093/ofid/ofaa105 PubMedWeb of Science®Google Scholar 3Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018; 23(8): 943-947. 10.1634/theoncologist.2018-0028 CASPubMedWeb of Science®Google Scholar 4Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020; 72(1): 31-40. 10.1002/art.41095 CASPubMedWeb of Science®Google Scholar 5Flaig T, Douros A, Bronder E, Klimpel A, Kreutz R, Garbe E. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2016; 41(6): 718-721. 10.1111/jcpt.12456 CASPubMedWeb of Science®Google Scholar 6Glund S, Krook A, Pannatier A. Role of interleukin-6 signaling in glucose and lipid metabolism. Acta Physiol. 2008; 192(1): 37-48. 10.1111/j.1748-1716.2007.01779.x CASPubMedWeb of Science®Google Scholar 7Devaud JC, Berger MM, Pannatier A, et al. Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness. Intensive Care Med. 2012; 38(12): 1990-1998. 10.1007/s00134-012-2688-8 CASPubMedWeb of Science®Google Scholar 8Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy. 2005; 25(10): 1348-1352. 10.1592/phco.2005.25.10.1348 CASPubMedWeb of Science®Google Scholar 9Barrientos-Vega R, Mar Sánchez-Soria M, Morales-García C, Robas-Gómez A, Cuena-Boy R, Ayensa-Rincon A. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med. 1997; 25(1): 33-40. 10.1097/00003246-199701000-00009 CASPubMedWeb of Science®Google Scholar 10Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012; 13: 138. 10.1186/1745-6215-13-138 PubMedWeb of Science®Google Scholar Citing Literature Volume92, Issue10Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐VIOctober 2020Pages 1791-1792 ReferencesRelatedInformation
Referência(s)